WuXi PharmaTech’s toxicology facility in Suzhou has received a statement of Good Laboratory Practice (GLP) from the Belgium Scientific Institute of Public Health on behalf of the Organization for Economic Cooperation and Development (OECD). The facility passed three GLP inspections covering organizational processes and conditions under which health safety studies are planned, performed, monitored, recorded, archived, and reported.
The inspection audited 22 studies in areas that included general toxicology, genetic toxicology, safety pharmacology, dermal irritation, skin phototoxicity, and immunology.
"The Belgian GLP statement for our toxicology facility is a further acknowledgment of the quality of our services, which meet the highest international standards," said Dr. Ge Li, chairman and chief executive officer of WuXi PharmaTech. "With this recognition, WuXi has further solidified its leadership in offering the highest-quality toxicology service in China. Toxicology is an important part of WuXi's comprehensive, fully integrated platform of services for our global and domestic pharmaceutical and biotech clients."